CINCINNATI, July 16 /PRNewswire-FirstCall/ --
CALL DATE: Wednesday, Aug. 6, 2008
TIME: 9:30 a.m. Eastern Time
HOST: Dr. Candace Kendle, Chairman and CEO
Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast on Wednesday, Aug. 6 at 9:30 a.m. Eastern Time to discuss its financial results for the Second Quarter ended June 30, 2008. A question and answer session will follow.
To access the live webcast, visit the company Web site at http://www.kendle.com or link to the Webcast directly at http://www.videonewswire.com/event.asp?id=50021 . Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Sept. 5, 2008. Please note that webcast participants will not be able to ask questions.
System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx .
Conference Call Instructions
To register (RSVP) for the telephone conference call, U.S. and Canadian participants should dial (800) 223-7104. Participants outside North America should dial (706) 645-6519.
To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on Sept. 5 by dialing (706) 645-9291 and entering conference ID number 55347808.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at http://www.kendle.com.
|SOURCE Kendle International Inc.|
Copyright©2008 PR Newswire.
All rights reserved